Literature DB >> 12644570

Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas.

Guoan Chen1, Hong Wang, Tarek G Gharib, Chiang-Ching Huang, Dafydd G Thomas, Kerby A Shedden, Rork Kuick, Jeremy M G Taylor, Sharon L R Kardia, David E Misek, Thomas J Giordano, Mark D Iannettoni, Mark B Orringer, Samir M Hanash, David G Beer.   

Abstract

We examined the expression of oncoprotein 18 (Op18) in 93 lung adenocarcinomas and 10 uninvolved lung samples using quantitative two-dimensional PAGE analysis with confirmation by mass spectrometry and two-dimensional Western blot analysis. mRNA expression was examined using oligonucleotide microarrays, and the cellular localization of the Op18 protein was examined using immunohistochemical analysis of tissue microarrays. Three phosphorylated forms and one unphosphorylated form of the Op18 protein were identified and found to be overexpressed in lung adenocarcinomas as compared with normal lung. The percentage of phosphorylated to total Op18 protein isoforms increased from 3.2% in normal lung to 7.9% in lung tumors. Both the phosphorylated and unphosphorylated Op18 proteins were significantly increased in poorly differentiated tumors as compared with moderately or well differentiated lung adenocarcinomas (p<0.03), suggesting that up-regulated expression of Op18 reflects a poor differentiation status and higher cell proliferation rates. This was further verified in A549 and SKLU1 lung adenocarcinoma cell lines by examining Op18 levels and phosphorylation status following treatment that altered either cell proliferation or differentiation. The increased expression of Op18 protein was significantly correlated with its mRNA level indicating that increased transcription likely underlies elevated expression of Op18. The overexpression of Op18 proteins in poorly differentiated lung adenocarcinomas and the elevated expression of the phosphorylated forms of Op18 may offer a new target for drug- or gene-directed therapy and may have potential utility as a tumor marker.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12644570     DOI: 10.1074/mcp.M200055-MCP200

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  22 in total

1.  The microtubule cytoskeleton is required for a G2 cell cycle delay in cancer cells lacking stathmin and p53.

Authors:  Bruce K Carney; Victoria Caruso Silva; Lynne Cassimeris
Journal:  Cytoskeleton (Hoboken)       Date:  2012-03-29

2.  Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma.

Authors:  Christopher W Seder; Wibisono Hartojo; Lin Lin; Amy L Silvers; Zhuwen Wang; Dafydd G Thomas; Thomas J Giordano; Guoan Chen; Andrew C Chang; Mark B Orringer; David G Beer
Journal:  Neoplasia       Date:  2009-04       Impact factor: 5.715

3.  High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.

Authors:  Henry D Reyes; Jeffrey Miecznikowski; Jesus Gonzalez-Bosquet; Eric J Devor; Yuping Zhang; Kristina W Thiel; Megan I Samuelson; Megan McDonald; Jean-Marie Stephan; Parviz Hanjani; Saketh Guntupalli; Krishnansu S Tewari; Floor Backes; Nilsa Ramirez; Gini F Fleming; Virginia Filiaci; Michael J Birrer; Kimberly K Leslie
Journal:  Gynecol Oncol       Date:  2017-05-19       Impact factor: 5.482

4.  Overexpression of stathmin is resistant to paclitaxel treatment in patients with non-small cell lung cancer.

Authors:  Ruifang Sun; Zhigang Liu; Lumin Wang; Weidong Lv; Jia Liu; Caixia Ding; Yong Yuan; Guangyan Lei; Changfu Xu
Journal:  Tumour Biol       Date:  2015-04-18

5.  Proteomics identifies multipotent and low oncogenic risk stem cells of the spleen.

Authors:  Francisco Dieguez-Acuña; Shohta Kodama; Yoshiaki Okubo; Ana Cristina Paz; Steven P Gygi; Denise L Faustman
Journal:  Int J Biochem Cell Biol       Date:  2009-12-18       Impact factor: 5.085

6.  Overexpression of stathmin 1 confers an independent prognostic indicator in nasopharyngeal carcinoma.

Authors:  Han-Ping Hsu; Chien-Feng Li; Sung-Wei Lee; Wen-Ren Wu; Tzu-Ju Chen; Kwang-Yu Chang; Shih-Shin Liang; Chia-Jung Tsai; Yow-Ling Shiue
Journal:  Tumour Biol       Date:  2013-11-12

7.  Hedgehog signaling regulates proliferation of prostate cancer cells via stathmin1.

Authors:  Moon-Kee Chung; Hyun-Jung Kim; Young-Suk Lee; Myoung-Eun Han; Sik Yoon; Sun-Yong Baek; Bong-Seon Kim; Jae-Bong Kim; Sae-Ock Oh
Journal:  Clin Exp Med       Date:  2009-09-25       Impact factor: 3.984

8.  Protein profiles associated with survival in lung adenocarcinoma.

Authors:  Guoan Chen; Tarek G Gharib; Hong Wang; Chiang-Ching Huang; Rork Kuick; Dafydd G Thomas; Kerby A Shedden; David E Misek; Jeremy M G Taylor; Thomas J Giordano; Sharon L R Kardia; Mark D Iannettoni; John Yee; Philip J Hogg; Mark B Orringer; Samir M Hanash; David G Beer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-22       Impact factor: 11.205

9.  Discovery and identification of potential biomarkers of pediatric acute lymphoblastic leukemia.

Authors:  Linan Shi; Jun Zhang; Peng Wu; Kai Feng; Jing Li; Zhensheng Xie; Peng Xue; Tanxi Cai; Ziyou Cui; Xiulan Chen; Junjie Hou; Jianzhong Zhang; Fuquan Yang
Journal:  Proteome Sci       Date:  2009-03-16       Impact factor: 2.480

10.  Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells.

Authors:  T-Y Jeon; M-E Han; Y-W Lee; Y-S Lee; G-H Kim; G-A Song; G-Y Hur; J-Y Kim; H-J Kim; S Yoon; S-Y Baek; B-S Kim; J-B Kim; S-O Oh
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.